

ALAN J. LAZARUS (State Bar No. 129767)
KRISTA L. COSNER (State Bar No. 213338)
DRINKER BIDDLE & REATH LLP
50 Fremont Street, 20th Floor
San Francisco, California 94105-2235
Telephone: (415) 591-7500
Facsimile: (415) 591-7510
Email: Alan.Lazarus@dbr.com
Email: Krista.Cosner@dbr.com

Attorneys for Defendant
SMITHKLINE BEECHAM CORPORATION d/b/a
GLAXOSMITHKLINE

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

ALLEN WILLIAMS, MARJORIE
WILLIAMS, PAUL WILLIAMS JR.,
HUGH WILSON, DORIS WRIGHT, ADA
YATES, EMMANUEL YORKE, LENA
YOUNG,

Plaintiffs,

v.

SMITHKLINE BEECHAM
CORPORATION d/b/a
GLAXOSMITHKLINE and MCKESSON
CORPORATION,

Defendants.

Case No.

**NOTICE OF REMOVAL AND
REMOVAL ACTION UNDER 28 U.S.C.
§ 1441(B) (DIVERSITY) and 28 U.S.C. §
1441(C) (FEDERAL QUESTION) OF
DEFENDANT SMITHKLINE
BEECHAM CORPORATION d/b/a
GLAXOSMITHKLINE**

TO THE CLERK OF THE COURT:

Defendant SMITHKLINE BEECHAM CORPORATION d/b/a
GLAXOSMITHKLINE ("GSK"), hereby removes to this court the state action described
below. Removal is warranted under 28 U.S.C. § 1441 because this is an action over
which this Court has original jurisdiction under 28 U.S.C. §§ 1331 and 1332.

I. BACKGROUND

1. On May 22, 2008, Plaintiffs Allen Williams, Marjorie Williams, Paul
Williams, Jr., Hugh Wilson, Doris Wright, Ada Yates, Emmanuel Yorke and Lena Young

1 (“Plaintiffs”), represented by The Miller Firm of Orange, Virginia, commenced this
 2 action in the Superior Court of the State of California for the County of San Francisco. A
 3 true and correct copy of the Complaint in the action is attached as Exhibit “A” to the
 4 Declaration of Krista L. Cosner in Support of Notice of Removal and Removal Action
 5 under 28 U.S.C. § 1441(b) and 28 U.S.C. § 1441(c) (Federal Question) of Defendant
 6 SmithKline Beecham Corporation d/b/a GlaxoSmithKline (hereinafter “Cosner Decl.”).

7 2. Neither defendant has yet been served with Plaintiffs’ Complaint. Cosner
 8 Decl. ¶ 9.

9 3. There have been no additional proceedings in the state court action.

10 4. This is one of many cases that have been filed recently in both federal and
 11 state court across the country involving the prescription drug Avandia®. Cosner Decl. ¶
 12 5. Plaintiffs’ counsel, The Miller Firm, has filed Avandia cases in both state and federal
 13 courts, but only in the cases filed in California has The Miller Firm named McKesson, or
 14 any alleged distributor of Avandia, as a defendant. Cosner Decl. ¶ 6.

15 5. On October 16, 2007, the Judicial Panel on Multidistrict Litigation
 16 (“JPML”) issued an order directing that then-pending Avandia-related cases be
 17 transferred and coordinated for pretrial proceedings in the United States District Court for
 18 the Eastern District of Pennsylvania, before the Honorable Cynthia M. Rufe, pursuant to
 19 28 U.S.C. § 1407. *See* Transfer Order, *In re Avandia Marketing, Sales Practices and*
 20 *Products Liability Litigation*, MDL 1871 (E.D.P.A.) (a true and correct copy of which is
 21 attached as Exhibit “B” to Cosner Decl.). Additional Avandia-related cases pending in
 22 federal court, which are common to the actions previously transferred to the Eastern
 23 District of Pennsylvania and assigned to Judge Rufe, are treated as potential tag-along
 24 actions. *See id.*; *see also* Rules 7.4 and 7.5, R.P.J.P.M.L. 199 F.R.D. 425, 435-36 (2001).
 25 GSK intends to seek the transfer of this action to that Multidistrict Litigation, *In re*
 26 *Avandia Marketing, Sales Practices and Products Liability Litigation*, MDL 1871, and
 27 shortly will provide the JPML with notice of this action pursuant to the procedure for
 28 “tag along” actions set forth in the rules of the JPML. Cosner Decl. ¶ 7.

6. As more fully set forth below, this case is properly removed to this Court pursuant to 28 U.S.C. § 1441 because GSK has satisfied the procedural requirements for removal and this Court has subject matter jurisdiction over this case pursuant to 28 U.S.C. §§ 1331 and 1332.

II. DIVERSITY JURISDICTION

7. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332 because this is a civil action in which the amount in controversy exceeds the sum of \$75,000, exclusive of costs and interest, and is between citizens of different states.

A. There is Complete Diversity of Citizenship Between Plaintiffs and Defendants

8. The Complaint names eight individual plaintiffs. *See* Cosner Decl., Exh. A, ¶¶ 10-17:

a. Plaintiff Allen Williams alleges that he is a “resident” of the State of Kentucky. Accordingly, at the time this action was commenced, he was a citizen of the State of Kentucky. *Id.* at ¶ 10.

b. Plaintiff Marjorie Williams alleges that she is a “resident” of the State of Louisiana. Accordingly, at the time this action was commenced, she was a citizen of the State of Louisiana. *Id.* at ¶ 11.

c. Plaintiff Paul Williams, Jr., alleges that he is a “resident” of the State of Tennessee. Accordingly, at the time this action was commenced, he was a citizen of the State of Tennessee. *Id.* at ¶ 12.

d. Plaintiff Hugh Wilson alleges that he is a “resident” of the State of Louisiana. Accordingly, at the time this action was commenced, he was a citizen of the State of Louisiana. *Id.* at ¶ 13.

e. Plaintiff Doris Wright alleges that she is a “resident” of the State of Louisiana. Accordingly, at the time this action was commenced, she was a citizen of the State of Louisiana. *Id.* at ¶ 14.

f. Plaintiff Ada Yates alleges that she is a “resident” of the State of

1 Kentucky. Accordingly, at the time this action was commenced, she was a citizen of the
2 State of Kentucky. *Id.* at ¶ 15.

3 g. Plaintiff Emmanuel Yorke alleges that he is a “resident” of the State
4 of Tennessee. Accordingly, at the time this action was commenced, he was a citizen of
5 the Tennessee. *Id.* at ¶ 16.

6 h. Plaintiff Lena Young alleges that she is a “resident” of the State of
7 Louisiana. Accordingly, at the time this action was commenced, she was a citizen of the
8 State of Louisiana. *Id.* at ¶ 17.

9 9. GSK is, and was at the time Plaintiffs commenced this action, a corporation
10 organized under the laws of the Commonwealth of Pennsylvania with its principal place
11 of business in Philadelphia, Pennsylvania, and therefore, is a citizen of Pennsylvania for
12 purposes of determining diversity. 28 U.S.C. § 1332(c)(1). Cosner Decl. ¶ 8.

13 10. The remaining named defendant, McKesson, is a Delaware corporation,
14 with its principal place of business in San Francisco, California. *See* Declaration of Greg
15 Yonko in Support of Notice of Removal and Removal Action under 28 U.S.C. § 1441(b)
16 and 28 U.S.C. § 1441(c) (Federal Question) of Defendant SmithKline Beecham
17 Corporation d/b/a GlaxoSmithKline, ¶ 3, attached to Cosner Decl. as Exhibit “C.”
18 Accordingly, there is complete diversity of citizenship between plaintiffs and defendants.

19 **B. The Amount In Controversy Requirement Is Satisfied**

20 11. It is apparent on the face of the Complaint that Plaintiffs seek an amount in
21 controversy in excess of \$75,000, exclusive of costs and interest.

22 12. Plaintiffs allege that they ingested Avandia, and, as a result, “have suffered
23 heart injury, excessive fluid retention, fluid-overload disease, liver damage, liver failure,
24 stroke and severe injury to the heart leading to cardiac arrest,” and have sustained,
25 “physical and financial damages including pain and suffering.” *See* Cosner Dec. Exh. A
26 at ¶ 40. Plaintiffs further allege that Plaintiffs “suffered severe and permanent physical
27 injuries” and endured substantial pain and suffering and extensive medical and surgical
28 procedures.” *See id.* at ¶ 57.

13. Plaintiffs allege that they have suffered economic loss, and have otherwise been physically, emotionally and economically injured, and that their injuries and damages are permanent and will continue into the future. *See id.* at ¶ 57.

14. Plaintiffs seek actual and punitive damages. *See id.*

15. Punitive damages are included in the calculation of the amount in controversy. *See Bell v. Preferred Life Assurance Society*, 320 U.S. 238, 240 (1943).

16. Given the allegations set forth above, the face of the Complaint makes clear that Plaintiffs seek in excess of \$75,000, exclusive of interest and costs. *See Simmons v. PCR Tech.*, 209 F. Supp. 2d 1029, 1031 (N.D. Cal. 2002).

C. The Citizenship of McKesson Must Be Ignored Because McKesson Has Not Been Properly Joined and Served

17. Under 28 U.S.C. § 1441(b), the so-called “forum defendant rule,” an action is removable only if none of the parties in interest, *properly joined and served* as defendants, is a citizen of the State in which such action is brought. 28 U.S.C § 1441(b) (emphasis added).

18. McKesson, although a citizen of California, has not yet been served with the Complaint in this case.

19. Accordingly, because there is complete diversity of citizenship and because no “properly joined and served defendant” is a citizen of this State, it is appropriate that this action be removed to this Court. *See Waldon v. Novartis Pharmaceuticals Corp.*, 2007 U.S. Dist. LEXIS 45809 (N.D. Cal. June 18, 2007); *see also* 28 U.S.C. § 1441(b).

D. The Citizenship Of McKesson Must Be Ignored Because McKesson Is Fraudulently Joined

20. A defendant is fraudulently joined, and its presence in the lawsuit is ignored for purposes of determining the propriety of removal, “if the plaintiff fails to state a cause of action against the resident defendant, and the failure is obvious according to the settled rules of the state.” *Morris v. Princess Cruises, Inc.*, 236 F.3d 1061, 1067 (9th Cir. 2001); *see also Hamilton Materials, Inc. v. Dow Chemical Corporation*, 494 F.3d 1203, 1206 (9th Cir. 2007).

21. McKesson is fraudulently joined because Plaintiffs have failed to make any specific material allegations against it. Plaintiffs do not even allege that they ingested Avandia that was distributed by McKesson, compelling the conclusion that Plaintiffs have fraudulently joined McKesson in an attempt to defeat diversity jurisdiction. *See, e.g., Brown v. Allstate Insur.*, 17 F. Supp. 2d 1134, 1137 (S.D. Cal. 1998) (finding in-state defendants fraudulently joined where “no material allegations against [the in-state defendants] are made”); *Lyons v. American Tobacco Co.*, No. Civ. A. 96-0881-BH-S, 1997 U.S. Dist. LEXIS 18365 (S.D. Ala. 1997) (holding that there is “no better admission of fraudulent joinder of [the resident defendant]” than the failure of the plaintiff “to set forth any specific ‘factual’ allegations” against them). Plaintiffs cannot cure this deficiency by simply relying on allegations directed toward “Defendants” or GSK alone.

22. Plaintiffs specifically allege that GSK was engaged in the business of designing, developing, manufacturing, testing, packaging, promoting, marketing, distributing, labeling and/or selling Avandia. *See Cosner Decl. Exh. A*, ¶ 19. Further, plaintiffs specifically allege that Avandia was created and marketed by GSK; that GSK had longstanding knowledge of Avandia-related dangers which GSK failed to adequately warn and disclose to consumers; that GSK concealed, suppressed and failed to disclose these referenced dangers; that GSK has represented and has continued to represent that it manufactures and/or sells safe and dependable pharmaceuticals; that GSK has failed to adequately warn or inform consumers, such as Plaintiffs or Plaintiffs’ prescribing physicians of known defects in Avandia; and that as a result of GSK’s omissions and/or misrepresentations, Plaintiffs ingested Avandia. *See id.* at ¶¶ 28, 32-34, 37, 39-40.

23. Plaintiffs also claim, however, that McKesson “packaged, distributed, supplied, sold, placed into the stream of commerce, labeled, described, marketed, advertised, promoted and purported to warn or inform users regarding the risks pertaining to, and assuaged concerns about [] Avandia.” *See id.* at ¶ 26. These allegations are inconsistent and contradictory, and courts have frequently viewed such inconsistencies as evidence of fraudulent joinder. *See Baisden v. Bayer Corp.*, 275 F. Supp. 2d 759, 762-

1 763. (S.D. W.Va. 2003).

2 24. Plaintiffs assert claims of: (1) negligence; (2) negligent failure to adequately
3 warn; (3) negligence per se; (4) negligent misrepresentation; (5) breach of express
4 warranty; (6) breach of implied warranty; (7) strict products liability – defective design;
5 (8) strict products liability – manufacturing and design defect; (9) strict products liability
6 – failure to adequately warn; (10) fraudulent misrepresentation; (11) violations of
7 California Unfair Trade Practices and Consumer Protection Law; (12) unjust enrichment;
8 (13) loss of consortium and (14) punitive damages. In these allegations, Plaintiffs aver
9 that collectively, “Defendants” or “Defendants GSK and McKesson,” defectively
10 designed and manufactured the product; concealed knowledge of unreasonably dangerous
11 risks associated with the product; failed to conduct adequate and sufficient pre-clinical
12 testing and post-marketing surveillance of the product; failed to provide FDA with
13 complete and adequate information regarding the product; failed to warn consumers
14 and/or their health care providers of certain risks associated with the product; failed to
15 utilize adequate and non-misleading labeling; and made affirmative misrepresentations
16 and omissions regarding the risks associated with taking Avandia. All of these claims are
17 substantively based on the design and manufacture of the product, failure to warn,
18 fraudulent concealment, and inadequate pre-clinical testing and post-marketing
19 surveillance. As a wholesale distributor of Avandia, McKesson played no role in its
20 testing, marketing or advertising. All McKesson did was pass along unopened boxes of
21 Avandia, in unadulterated form, to hospitals and other businesses in the healthcare
22 industry. *See* Cosner Decl. Exh. C, ¶¶ 6-7.¹

23
24
25 ¹ The Declaration of McKesson’s representative, Greg Yonko may be considered by the Court in
26 determining whether McKesson is fraudulently joined. *Maffei v. Allstate California Ins. Co.*, 412
27 F.Supp.2d 1049 (E.D. Cal. 2006) (“[t]he court may pierce the pleadings, consider the entire record, and
28 determine the basis of joinder by any means available”) *citing* *Lewis v. Time, Inc.*, 83 F.R.D. 455 (E.D.
Cal. 1979) (“it is well settled that upon allegations of fraudulent joinder...federal courts may look beyond
the pleadings to determine if the joinder...is a sham or fraudulent device to prevent removal”). *See also*
Ritchey v. Upjohn Drug Co., 139 F.3d 1313, 1318-19 (9th Cir. 1998) (evidence may be presented by the
removing party that there is no factual basis for the claims pleaded against the local defendant).

25. Further, based on the “learned intermediary” doctrine, McKesson bore no duty to warn Plaintiffs. The “learned intermediary” doctrine, the foundation of prescription drug product liability law, provides that the duty to warn about a drug’s risks runs from the manufacturer to the physician (the “learned intermediary”), and then from the physician to the patient. *See Brown v. Superior Court (Abbott Labs.)*, 44 Cal. 3d 1049, 1061-62, n.9 (1988); *Carlin v. Superior Court (Upjohn Co.)*, 13 Cal. 4th 1104, 1116 (1996). It is the physician, and only the physician, who is charged with prescribing the appropriate drug and communicating the relevant risks to the patient. *See Brown*, 44 Cal. 3d at 1061-62.

26. GSK and the FDA prepared the information to be included with the prescription drug, Avandia, with the FDA having final approval of the information that could be presented. Once the FDA has determined the form and content of the information, it is a violation of federal law to augment the information. *See* 21 U.S.C. §331(k) (prohibiting drug manufacturers and distributors from causing the “alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling” of an FDA-approved drug held for sale); *Brown v. Superior Court*, 44 Cal.3d 1049, 1069 n.12 (noting that the FDA regulates the testing, manufacturing, and marketing of drugs, including the content of their warning labels). Therefore, any safety and warning information McKesson had about Avandia would have come from GSK in the form of FDA-approved packaging and labeling. McKesson could not change the labeling it was given by GSK as approved by the FDA without violating federal law. No duty can be found where it requires a party to violate the law to fulfill it.

27. As such, given the lack of a causal connection between the injuries alleged by Plaintiffs and McKesson’s conduct, as well as the absence of any legal or factual basis for Plaintiffs’ claims against McKesson, McKesson’s joinder is fraudulent and its citizenship should be ignored for purposes of determining the propriety of removal.

III. FEDERAL QUESTION JURISDICTION

28. This Court has federal question jurisdiction over Plaintiffs’ claims under

1 28 U.S.C. § 1331 and the principles set forth in *Grable & Sons Metal Prods., Inc. v.*
 2 *Darue Eng'g & Mfg.*, 125 S. Ct. 2363 (2005).

3 29. As more fully explained below, Plaintiffs have made violations of federal
 4 law critical elements of several of their claims.

5 **A. Plaintiffs' Claims Require Construction and Application of the**
 6 **FDCA and Its Implementing Regulations**

7 30. Count III of Plaintiffs' Complaint, "Negligence Per Se," explicitly alleges
 8 that defendants violated federal law. Plaintiffs claim, *inter alia*, that "[d]efendants
 9 violated the Federal Food, Drug and Cosmetic Act, 21 U.S.C. Section 301 *et seq.*, related
 10 amendments and codes and federal regulations provided thereunder, and other applicable
 11 laws, statutes, and regulations." *See* Cosner Decl. Exh A, ¶ 61.

12 31. Plaintiffs further claim that "[d]efendants' acts constituted an adulteration
 13 and/or misunderstanding [*sic*] as defined by the Federal Food, Drug and Cosmetic Act,
 14 21 U.S.C. § 331. . . ." *See* Cosner Decl. Exh A, ¶ 63.

15 32. Moreover, Count II of the Plaintiffs' Complaint, "Negligent Failure to
 16 Adequately Warn," and Count IX, "Strict Products Liability – Failure to Adequately
 17 Warn," also require construction and application of the FDCA and implementing federal
 18 regulations, which govern approval of prescription drugs and regulate prescription drug
 19 manufacturers' public and promotional statements, including all aspects of warnings and
 20 labeling.

21 33. As a currently-marketed prescription drug, Avandia is subject to extensive
 22 regulation by the FDA. The FDCA requires the FDA to ensure that "drugs are safe and
 23 effective" for their intended uses, 21 U.S.C. § 393(b)(2)(B), in part by "promptly and
 24 officially reviewing clinical research and taking appropriate action on the marketing of
 25 regulated products." 21 U.S.C. § 393(b)(1). The Secretary of the FDA has the authority
 26 to promulgate regulations to enforce the FDCA, which are codified in the *Code of*
 27 *Federal Regulations*, 21 C.F.R. § 200, *et seq.* *See* 21 U.S.C. § 371(a).

28 34. To accomplish its purpose, the FDA maintains a Center for Drug

1 Evaluation and Research (the "CDER"). The CDER regulates pharmaceutical
 2 companies' development, testing and research, and manufacture of drugs. The CDER
 3 examines data generated by these companies to conduct a risk/benefit analysis and make
 4 an approval decision. The CDER also ensures truthful advertising for prescription drugs,
 5 in part by approving Package Inserts that properly outline benefit and risk information.
 6 Once drugs are marketed, the CDER continues to monitor them for unexpected health
 7 risks that may require public notification, a change in labeling, or removal of the product
 8 from the market. In short, the CDER evaluates and monitors the effectiveness and safety
 9 of prescription drugs. See <http://www.fda.gov/cder/about/faq/default.htm>.

10 35. Promotional communications to physicians about Avandia are contained
 11 within, and restricted by, warning, labeling, and promotional materials, such as the
 12 Package Insert, that are approved and monitored by the FDA to ensure the provision of
 13 accurate information about the drug's respective risks and benefits. Under federal
 14 regulations, even claims in promotional labeling or advertising must be consistent with
 15 approved labeling. 21 C.F.R. § 202.1(e)(4) (2005).

16 36. The FDA's responsibility to regulate prescription drugs sold in the United
 17 States, and to enforce laws with respect to such drugs, inclusive of the precise content
 18 and format of prescription drug labeling (*e.g.*, the instructions, warning, precautions,
 19 adverse reaction information provided by manufacturers, and marketing materials), is
 20 plenary and exclusive. See 21 U.S.C. § 301, *et seq*

21 37. Plaintiffs have explicitly alleged violations of federal law in their
 22 "Negligence Per Se" claim, and have made alleged violations of federal law a critical
 23 element of their "Negligent Failure to Adequately Warn" and "Strict Products Liability –
 24 Failure to Adequately Warn" claims. Accordingly, Plaintiffs' claims necessarily raise
 25 substantial federal questions by requiring the Court to construe and apply the FDCA and
 26 its implementing regulations.

27 **B. Federal Control of Drug Labeling and Warning**

28 38. On January 24, 2006, the FDA announced a rule that includes a detailed

1 and emphatic statement of the FDA's intention that its regulation and approval of
 2 prescription drug labeling preempt most state law claims related to the adequacy of
 3 prescription drug warnings because such claims frustrate "the full objectives of the
 4 Federal law." *See* Requirements on Content and Format of Labeling for Human
 5 Prescription Drug and Biologic Products, 71 Fed. Reg. 3922, 3934 (Jan. 24, 2006) ("FDA
 6 believes that under existing preemption principles, FDA approval of labeling under the
 7 act. . . . preempts conflicting or contrary State law."). *See also In re Bextra and*
 8 *Celebrex Marketing*, 2006 WL 2374742 (N.D. Cal., August 16, 2006) (Celebrex
 9 decision); *In re Bextra and Celebrex Marketing*, 2006 WL 2472484 (N.D. Cal., August
 10 24, 2006) (Bextra decision);

11 39. Plaintiffs allege that GSK failed to disclose certain risks of Avandia. *See*
 12 *e.g.*, Cosner Decl. Exh. A, ¶¶ 32-34. This allegation necessarily requires Plaintiffs to
 13 establish that the FDA, which has exclusive jurisdiction over the labeling of drugs, would
 14 have approved the warning the Plaintiffs allege should have been given.

15 40. Accordingly, there is a substantial federal question with respect to whether
 16 Plaintiffs can claim that GSK violated state law in light of the FDA's control of
 17 Avandia's labeling and warning and its position on conflict preemption.

18 C. The Federal Interest In Providing A Forum

19 41. The federal government has a strong interest in having a federal court
 20 decide several of the issues in this case. Among these issues are:

- 21 a. whether any conduct of GSK violated any federal laws or
- 22 regulations related to the labeling and marketing of Avandia; and
- 23 b. whether the FDA-approved Avandia label was false and misleading,
- 24 as alleged by Plaintiff, and whether a state may impose liability on
- 25 GSK for not providing more information regarding alleged risks, as
- 26 Plaintiff contends GSK should have done.

27 42. Plaintiffs' claims may be vindicated or defeated only by construction of
 28 federal statutes and regulations. The availability of a federal forum to protect the

important federal interests at issue is therefore consistent with *Grable*, and determination by a federal court of the substantial and disputed federal issues that lie at the heart of this case would not “disturb any congressionally approved balance of federal and state judicial responsibilities.” *Grable*, 125 S. Ct. at 2368.

IV. CONFORMANCE WITH PROCEDURAL REQUIREMENTS

43. This Court has jurisdiction over this matter based on federal question and diversity of citizenship, and the present lawsuit may be removed from the Superior Court of the State of California for the County of San Francisco, and brought before the United States District Court for the Northern District of California pursuant to 28 U.S.C. §§ 1331, 1332 and 1441.

44. Neither GSK nor McKesson have been served with Plaintiffs’ Complaint. Cosner Decl. ¶ 9. Therefore, this Removal has been timely filed. *See* 28 U.S.C. § 1446(b).

45. Since neither GSK nor McKesson have been “properly joined and served” at the time of filing this Removal, GSK is entitled to removal under the plain language of 28 U.S.C. § 1441(b). *See Waldon v. Novartis Pharmaceuticals Corp.*, 2007 U.S. Dist. LEXIS 45809 (N.D. Cal. June 18, 2007). *See also* 28 U.S.C. § 1441(b); Cosner Decl. ¶ 9.

46. Moreover, McKesson’s consent to remove is not necessary because it is fraudulently joined. *See e.g., Easley v. 3M Company, et al.*, 2007 WL 2888335 (N.D. Cal. 2007) *citing Emrich v. Touche Ross & Co.*, 846 F.2d 1190, 1193 n.1 (9th Cir. 1988).

47. The United States District Court for the Northern District of California is the federal judicial district encompassing the Superior Court of the State of California for the County of San Francisco, where this suit was originally filed. Venue therefore is proper in this district under 28 U.S.C. § 1441(a).


48. Pursuant to the provisions of 28 U.S.C § 1 446(d), GSK will promptly file a copy of this Notice of Removal with the clerk of the Superior Court of the State of California for the County of San Francisco, where this suit was originally filed.

1 49. Defendant reserves the right to amend or supplement this Notice of
2 Removal.

3 **WHEREFORE**, GSK respectfully removes this action from the Superior Court of
4 the State of California for the County of San Francisco to the United States District Court
5 for the Northern District of California, pursuant to 28 U.S.C. § 1441.

6
7 Dated: May 27 2008

DRINKER BIDDLE & REATH LLP

8 
9 KRISTA L. COSNER

10 Attorneys for Defendant
11 SMITHKLINE BEECHAM
12 CORPORATION d/b/a
13 GLAXOSMITHKLINE
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28